Anxiety Disorders and Depression Treatment Market Size, Share, Growth, Trends, and Global Industry Analysis: By Product Type (MAOIs (Monoamine Oxidase inhibitors), Atypical Antipsychotics, Benzodiazepines, Anticonvulsants, Beta-Blockers, SRIs (Selective Serotonin Reuptake Inhibitors), SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors), TeCAs (Tetracyclic Antidepressants), TCAs (Tricyclic Antidepressants), and Others), By Anxiety Type (Generalized Anxiety Disorder, Social Anxiety Disorder, Panic Disorder, Phobias, and Obsessive Compulsive Disorder), By Depression Type (Major Depressive Disorder, Persistent Depressive Disorder, Bipolar Disorder, and Seasonal Affective Disorder), By Patient Age Group (Adults, Adolescents, and Children), By Distribution Channel (Hospital Pharmacies, Online Pharmacies, and Others), and Region Forecast 2020-2031

Anxiety Disorders and Depression Treatment Market size was valued at US$ 14,543.9 million in 2024 and is expected to reach US$ 19,268.0 million by 2031, growing at a significant CAGR of 4.1% from 2025-2031. Moreover, in the USA, the anxiety disorders and depression treatment market size was valued at US$ 6,289.3 million in 2024 and is projected to reach US$ 8,790.8 million by 2031, growing at a CAGR of 4.9% from 2025-2031.

The market is experiencing steady growth, driven by the increasing global burden of mental health conditions. According to the World Health Organization (WHO), anxiety disorders affected over 301 million people worldwide in 2019, while depression impacted nearly 280 million individuals. The COVID-19 pandemic increased this crisis, triggering a 25% rise in the prevalence of anxiety and depression in its first year alone. These conditions not only impair quality of life but also contribute significantly to economic losses, with an estimated 12 billion working days lost each year due to depression and anxiety, costing the global economy over $1 trillion annually. Treatment options encompass a range of pharmacological and non-pharmacological interventions, including cognitive behavioral therapy, antidepressants, anxiolytics, and integrative approaches like medical nutrition therapy.

Increasing recognition of the gut-brain axis, personalized medicine advancements, and digital mental health tool innovations are further shaping the treatment landscape. Governments and healthcare organizations are responding by integrating mental health services into primary care and promoting early diagnosis and holistic management. As awareness rises and stigma declines, the market is expected to continue expanding, underscoring mental health’s critical role in overall well-being.

Facts and Figures

• According to the WHO, over 700,000 people die by suicide each year, and depression is a leading cause. Suicide is the fourth leading cause of death among 15–29-year-olds, reinforcing the urgent need for effective mental health interventions and treatment availability worldwide.
• As per the Global Burden of Disease Study 2019 (GBD 2019), anxiety disorders accounted for 28.68 million disability-adjusted life years (DALYs) globally, while depressive disorders accounted for 46.04 million DALYs, highlighting their significant impact on global health and productivity.
• During the first year of the COVID-19 pandemic, the global prevalence of both anxiety and depression increased by 25%, as reported by the WHO, emphasizing the urgent demand for scalable and accessible treatment solutions.
• In the United States, the National Institute of Mental Health (NIMH) states that 31.9% of adolescents aged 13–18 have experienced an anxiety disorder, while 21 million U.S. adults (8.3% of all adults) reported at least one major depressive episode in 2021.
• Key Takeaways
• The market size was valued at US$ 14,543.9 million in 2024 and is projected to reach US$ 19,268.0 million by 2031, growing at a CAGR of 4.1% from 2025-2031, driven by rising mental health awareness and increased integration of treatment into primary care systems.
• According to the World Health Organization (WHO), over 301 million people globally were affected by anxiety disorders in 2019, while depression impacted nearly 280 million individuals, making these conditions among the most prevalent mental health challenges worldwide.

Key Developments:

• January 2025: The FDA approved SPRAVATO® (esketamine) nasal spray as the first standalone treatment for adults with major depressive disorder (MDD) who haven't responded to at least two oral antidepressants. Backed by clinical trials, SPRAVATO® offers rapid symptom relief, with noticeable effects in as little as 24 hours.
• February 2023: The FDA accepted Biogen and Sage Therapeutics' New Drug Application for zuranolone, a 14-day, once-daily oral treatment for major depressive disorder (MDD) and postpartum depression (PPD), granting it Priority Review. Zuranolone offers rapid symptom relief and could address a major unmet need in depression treatment, pending approval.

Anxiety Disorders and Depression Treatment Market Segmentation:

Based on the Product Type:

• MAOIs (Monoamine Oxidase inhibitors)
• Atypical Antipsychotics
• Benzodiazepines
• Anticonvulsants
• Beta-Blockers
• SRIs (Selective Serotonin Reuptake Inhibitors)
• SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors)
• TeCAs (Tetracyclic Antidepressants)
• TCAs (Tricyclic Antidepressants)
• Others

Selective Serotonin Reuptake Inhibitors (SSRIs) are the most commonly prescribed class for anxiety and depression treatment. According to national health sources, fluoxetine, escitalopram, and sertraline remain top choices in the U.S. and India due to their proven efficacy, tolerability, and widespread availability through public and private healthcare systems.

Based on the Anxiety Type:

• Generalized Anxiety Disorder
• Social Anxiety Disorder
• Panic Disorder
• Phobias
• Obsessive Compulsive Disorder 

Social Anxiety Disorder (SAD) is a prevalent segment in the anxiety disorders treatment market, affecting approximately 7% of U.S. adults annually, with around 15 million individuals impacted. This significant prevalence underscores the critical need for effective therapeutic interventions to manage and alleviate SAD symptoms

Based on the Depression Type:

• Major Depressive Disorder
• Persistent Depressive Disorder
• Bipolar Disorder
• Seasonal Affective Disorder

Major Depressive Disorder (MDD) is the most prevalent form of depression, affecting approximately 8.3% of U.S. adults, equating to 21 million individuals. Notably, the highest prevalence is among individuals aged 18-25 years, with 18.6% affected. This underscores the critical need for targeted interventions and accessible mental health services for this demographic.

Based on the Patient Age Group:

• Adults
• Adolescents
• Children

Adolescents represent a significant segment in the depression treatment market. In 2021, approximately 3.7 million U.S. adolescents aged 12 to 17 experienced at least one major depressive episode with severe impairment, accounting for 14.7% of this age group. Notably, only 44.2% of these adolescents received treatment, highlighting a substantial gap in mental health care accessibility.

Based on the Distribution Channel:

• Hospital Pharmacies
• online Pharmacies
• Others

Hospital pharmacies play a crucial role in the distribution of medications for anxiety and depression treatments. They provide patients with access to essential medications and ensure proper management of these treatments within healthcare facilities. The integration of hospital pharmacies into patient care teams enhances medication adherence and monitoring, contributing significantly to effective mental health management.